Annex VIII of the IVDR sets out seven classification rules, and most of them weigh a device's technical sophistication against its risk profile. Rule 7 and Rule 3 both do that kind of balancing. Rule 1 does not. It asks one question — what does this result decide — and if the answer is donation safety or epidemic risk, the device is Class D regardless of how simple the assay itself is. A rapid lateral-flow screen and a fully automated multiplex platform can land in the identical class, because Rule 1 classifies the decision the test supports, not the instrument that produces it.
The two indents, read literally
Rule 1 has two separate triggers, and manufacturers routinely argue themselves out of the one that actually applies. The first indent covers devices intended to detect the presence of, or exposure to, a transmissible agent in blood, blood components, cells, tissues, or organs, or in derivatives of these, in order to determine their suitability for transfusion, transplantation, or cell administration — the donation-safety case. The second indent covers devices intended to detect the presence of a transmissible agent that causes a life-threatening disease with a high or suspected high risk of propagation — the public-health case, which applies whether or not a donation is involved. A test built purely for individual patient diagnosis or treatment monitoring, with no donation-screening purpose and no life-threatening propagation profile, sits outside Rule 1 entirely and is classified under one of the other six rules instead.
Why format doesn't rescue the classification
The pattern that catches teams off guard: a company builds a simpler, faster, or cheaper version of an existing blood-safety screen and assumes the simplified format earns a lower class. It does not. Historically, HIV and hepatitis B detection and confirmation assays — whatever their format — have been treated as Rule 1 Class D devices under Annex VIII, precisely because the intended use is donation screening or life-threatening-disease detection, not because the assay chemistry is complex. A point-of-care rapid test used to screen a blood donation carries the same Rule 1 classification as a laboratory-based automated platform doing the identical job. If your in vitro diagnostics intended-use statement describes donation suitability or epidemic-risk detection, assume Class D until the classification analysis proves otherwise — not the reverse.
- Donation-safety screening. Any device whose result determines whether blood, tissue, cells, or an organ is suitable for transfusion, transplantation, or cell administration falls under the first indent, regardless of panel size or platform.
- Life-threatening, highly transmissible disease detection. The second indent applies independent of any donation context — a test used purely for individual diagnosis still triggers Rule 1 if the agent itself meets that threshold.
- The higher-class rule governs. Where a device's performance specifications could plausibly bring more than one Annex VIII rule into play, the general implementing rules direct the manufacturer to the rule producing the higher classification.
- Format is not a defense. Simplifying the assay, moving it to a point-of-care format, or multiplexing it onto a broader panel does not move a Rule 1 device out of Class D.
Rule 1 doesn't ask how sophisticated your assay is. It asks what happens if the result is wrong — and for donation safety and epidemic risk, the regulation has already answered that question. Why Rule 1 overrides technical-risk balancing
What Class D actually commits you to
Classification is the first decision, not the only one. A Rule 1 Class D device moves into the IVDR's strictest conformity-assessment track: notified body review of the full technical documentation, and — where the European Commission has designated an EU Reference Laboratory for that analyte category — EURL verification of the manufacturer's performance claims against the laboratory's own testing before the notified body can issue a certificate. Confirm current EURL designations for your specific analyte before you build a submission timeline; the set of designated categories has grown since the regulation entered into application, and an undesignated category today may not stay that way. Layer on top of that the Class D scientific validity and performance evaluation documentation requirements under Annex XIII — the most extensive evidentiary package the IVDR imposes — and Rule 1 is less a classification question than a program-planning one.
- Test the intended purpose against both indents separately. Donation-safety suitability and life-threatening propagation risk are independent triggers — check each on its own terms.
- Don't let assay simplicity argue down the class. A simplified or point-of-care format does not change what the result is used to decide.
- Confirm EURL scope for your analyte early. Designated-category verification adds real time and logistics to the critical path.
- Start the Class D evidence plan before the submission, not after a deficiency letter. Scientific validity, analytical performance, and clinical performance documentation under Annex XIII take longest to assemble retroactively.
None of this is a reason to avoid the blood-safety or infectious-disease space — it's a reason to plan the program around the classification you actually have, not the one you hoped for. Companies that run the Rule 1 analysis against the literal intended-use statement, confirm EURL scope before committing to a timeline, and start the Annex XIII evidence package early are the ones whose notified body review moves on schedule. Companies that discover the classification during a transition-deadline scramble are the ones who don't. If you're scoping a new assay in this space, our diagnostics regulatory strategy work exists for exactly this classification-to-conformity handoff.
Frequently asked questions
Does every infectious-disease test automatically land in Class D under Rule 1?
No. Rule 1 is narrower than "infectious disease." It applies when a device detects a transmissible agent in blood, blood components, cells, tissues, or organs to judge their suitability for transfusion, transplantation, or cell administration, or when it detects a transmissible agent causing a life-threatening disease with a high or suspected high risk of propagation. An assay used purely for individual diagnosis or patient management outside those two scenarios is classified under a different Annex VIII rule, not Rule 1.
What is the difference between Rule 1's two indents?
The first indent is about donation safety: screening blood, tissue, cell, or organ donations before they are used in someone else. The second indent is about public-health propagation risk: detecting an agent that causes a life-threatening, highly transmissible disease, independent of any donation context. A device only needs to satisfy one indent to be Class D; it does not need to meet both.
What happens after a device is classified Class D under Rule 1?
Class D triggers the IVDR's strictest conformity-assessment route: notified body review of the technical documentation, EU reference laboratory (EURL) verification of the manufacturer's performance claims where an EURL has been designated for that analyte category, and the most demanding performance evaluation and post-market surveillance obligations in the regulation. Confirm current EURL designations for your analyte category before finalizing your submission timeline, since the list of designated categories has expanded since IVDR entered into application.
Sources & further reading
- Regulation (EU) 2017/746 of the European Parliament and of the Council (IVDR), Annex VIII — Classification Rules. eur-lex.europa.eu
- Medical Device Coordination Group. MDCG 2020-16 rev.4 — Guidance on Classification Rules for In Vitro Diagnostic Medical Devices under Regulation (EU) 2017/746. health.ec.europa.eu
This article is provided for general informational purposes and reflects the regulatory landscape as of November 2026. It is not legal or regulatory advice. Confirm current Annex VIII classification guidance and EU Reference Laboratory designations with a notified body or qualified counsel before acting.